Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008

D. E. Furst; E. C. Keystone; B. Kirkham; R. Fleischmann; P. Mease; F. C. Breedveld; J. S. Smolen; J. R. Kalden; G. R. Burmester; J. Braun; P. Emery; K. Winthrop; B. Bresnihan; F. De Benedetti; T. Dörner; A. Gibofsky; M. H. Schiff; J. Sieper; N. Singer; P. L C M Van Riel; M. E. Weinblatt; M. H. Weisman

doi:10.1136/ard.2008.100834

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008

D. E. Furst, E. C. Keystone, B. Kirkham, R. Fleischmann, P. Mease, F. C. Breedveld, J. S. Smolen, J. R. Kalden, G. R. Burmester, J. Braun, P. Emery, K. Winthrop, B. Bresnihan, F. De Benedetti, T. Dörner, A. Gibofsky, M. H. Schiff, J. Sieper, N. Singer, P. L C M Van RielM. E. Weinblatt, M. H. Weisman

Ospedale Pediatrico Bambino Gesu

Research output: Contribution to journal › Article › peer-review

Abstract

Rituximab is effective in patients with an inadequate response to MTX for whom conventional DMARDS have failed or have one or more TNFα blocking agents. The safety of rituximab is still being defined. It is hoped that this statement, based on the best evidence available at this time, and modified by expert opinion, will facilitate the optimal use of these agents.

Original language	English
Journal	Annals of the Rheumatic Diseases
Volume	67
Issue number	SUPPL. 3
DOIs	https://doi.org/10.1136/ard.2008.100834
Publication status	Published - Dec 2008

ASJC Scopus subject areas

Rheumatology
Immunology
Biochemistry, Genetics and Molecular Biology(all)
Immunology and Allergy

Access to Document

10.1136/ard.2008.100834

Cite this

Furst, D. E., Keystone, E. C., Kirkham, B., Fleischmann, R., Mease, P., Breedveld, F. C., Smolen, J. S., Kalden, J. R., Burmester, G. R., Braun, J., Emery, P., Winthrop, K., Bresnihan, B., De Benedetti, F., Dörner, T., Gibofsky, A., Schiff, M. H., Sieper, J., Singer, N., ... Weisman, M. H. (2008). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Annals of the Rheumatic Diseases, 67(SUPPL. 3). https://doi.org/10.1136/ard.2008.100834

Furst, DE, Keystone, EC, Kirkham, B, Fleischmann, R, Mease, P, Breedveld, FC, Smolen, JS, Kalden, JR, Burmester, GR, Braun, J, Emery, P, Winthrop, K, Bresnihan, B, De Benedetti, F, Dörner, T, Gibofsky, A, Schiff, MH, Sieper, J, Singer, N, Van Riel, PLCM, Weinblatt, ME & Weisman, MH 2008, 'Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008', Annals of the Rheumatic Diseases, vol. 67, no. SUPPL. 3. https://doi.org/10.1136/ard.2008.100834

@article{27840148831347f1aa5c0108a93aaa94,

title = "Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008",

abstract = "Rituximab is effective in patients with an inadequate response to MTX for whom conventional DMARDS have failed or have one or more TNFα blocking agents. The safety of rituximab is still being defined. It is hoped that this statement, based on the best evidence available at this time, and modified by expert opinion, will facilitate the optimal use of these agents.",

author = "Furst, {D. E.} and Keystone, {E. C.} and B. Kirkham and R. Fleischmann and P. Mease and Breedveld, {F. C.} and Smolen, {J. S.} and Kalden, {J. R.} and Burmester, {G. R.} and J. Braun and P. Emery and K. Winthrop and B. Bresnihan and {De Benedetti}, F. and T. D{\"o}rner and A. Gibofsky and Schiff, {M. H.} and J. Sieper and N. Singer and {Van Riel}, {P. L C M} and Weinblatt, {M. E.} and Weisman, {M. H.}",

year = "2008",

month = dec,

doi = "10.1136/ard.2008.100834",

language = "English",

volume = "67",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "SUPPL. 3",

}

TY - JOUR

T1 - Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008

AU - Furst, D. E.

AU - Keystone, E. C.

AU - Kirkham, B.

AU - Fleischmann, R.

AU - Mease, P.

AU - Breedveld, F. C.

AU - Smolen, J. S.

AU - Kalden, J. R.

AU - Burmester, G. R.

AU - Braun, J.

AU - Emery, P.

AU - Winthrop, K.

AU - Bresnihan, B.

AU - De Benedetti, F.

AU - Dörner, T.

AU - Gibofsky, A.

AU - Schiff, M. H.

AU - Sieper, J.

AU - Singer, N.

AU - Van Riel, P. L C M

AU - Weinblatt, M. E.

AU - Weisman, M. H.

PY - 2008/12

Y1 - 2008/12

N2 - Rituximab is effective in patients with an inadequate response to MTX for whom conventional DMARDS have failed or have one or more TNFα blocking agents. The safety of rituximab is still being defined. It is hoped that this statement, based on the best evidence available at this time, and modified by expert opinion, will facilitate the optimal use of these agents.

AB - Rituximab is effective in patients with an inadequate response to MTX for whom conventional DMARDS have failed or have one or more TNFα blocking agents. The safety of rituximab is still being defined. It is hoped that this statement, based on the best evidence available at this time, and modified by expert opinion, will facilitate the optimal use of these agents.

UR - http://www.scopus.com/inward/record.url?scp=56749132218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56749132218&partnerID=8YFLogxK

U2 - 10.1136/ard.2008.100834

DO - 10.1136/ard.2008.100834

M3 - Article

C2 - 19022808

AN - SCOPUS:56749132218

SN - 0003-4967

VL - 67

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - SUPPL. 3

ER -

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this